个人简介：

Shirley Liu, PhD Chief Executive Officer Co-Founder Dr. Xiaole Shirley Liu co-founded GV20 Therapeutics in 2016 and became the CEO of GV20 in 2022. She was a Professor of Biostatistics and Computational Biology at Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health and co-director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute. Her computational biology work refined our understanding of hormone receptor therapies, epigenetic inhibitors, gamma-secretase inhibitors, receptor tyrosine kinase inhibitors, and immune checkpoint inhibitors in different cancers. Dr. Liu is a highly cited researcher with a prodigious publication record that includes more than 200 papers published by her group, many in high-profile journals and highly cited. Shirley received the Sloan Research Fellowship (2008), has been a Breast Cancer Research Foundation Investigator (2017) and became a Fellow of ISCB (2019). In addition, she was recognized with the Benjamin Franklin Award for Open Access in the Life Sciences and the ISCB Innovator Award in 2020. Recently, she was selected by the American Institute for Medical and Biological Engineering (AIMBE) to its 2022 College of Fellows.

公司简介：

由哈佛大学终身教授刘小乐Shirley Liu创立，是一家致力于通过应用基因组学、计算生物学、生物大数据和人工智能，来筛选癌症药物的有效靶点和开发全人源抗体药物的first-in-class新药研发公司。 

公司已拥有全套自主知识产权的“Atlas全基因组靶点筛选平台”和“Phial AI抗体药设计平台”。其中Atlas平台是中国首个基于功能基因组学的肿瘤新药靶标筛选平台，在肿瘤功能基因组学、癌症免疫治疗和生物大数据技术上具有国际领先优势。而寻百会Phial AI抗体药设计平台是世界上唯一一个可以基于靶点设计全新抗体序列的计算平台，具有靶点覆盖面广、准确度高、研发周期短、功能性强以及成药性好等优点。基于这两大平台，公司已有多条管线药物处于临床开发的不同阶段，并与全球大型制药企业有多种合作。我们希望通过AI赋能制药，能够迅速开发高效的抗肿瘤新药，通过精准医疗彻底治愈癌症！

公司官网：http://www.bioxbh.com/